ALPHAMAB, 3D Medicines, and Glenmark Reach $700 Million Licensing Agreement for KN035

In a significant development, ALPHAMAB Biopharmaceuticals, in collaboration with 3D Medicines, has announced a groundbreaking licensing agreement worth over $700 million for their PD-L1 antibody drug, KN035. The agreement grants Glenmark Pharmaceuticals Ltd., through its subsidiary Glenmark Specialty S.A., exclusive rights for the development and commercialization of KN035 in certain regions. This strategic partnership is poised to revolutionize the oncology market and pave the way for enhanced patient care and treatment options.

Licensing Agreement Details:
Under the terms of the licensing agreement, ALPHAMAB and 3D Medicines will receive a total of $700.8 million from Glenmark, including upfront and milestone payments. The agreement also stipulates that Glenmark will bear the costs associated with the development and commercialization of KN035 in the Indian subcontinent, Asia-Pacific (excluding Singapore, Thailand, and Malaysia), the Middle East and Africa, Russia, the Commonwealth of Independent States, and Latin America. In return, ALPHAMAB retains exclusive global manufacturing rights for KN035 for any purpose.

Strategic Advantages and Market Impact:
This collaboration empowers ALPHAMAB to leverage Glenmark's existing resources and expertise to establish a favorable market position for KN035 in the aforementioned regions. With its unique design, KN035 offers advantages in terms of efficacy, safety, convenience, and compliance, as it eliminates the need for intravenous infusion, potentially reducing healthcare costs. The licensing agreement is expected to have a positive impact on the commercialization of KN035, expanding its availability to patients and contributing to improved treatment outcomes.

Background on KN035 and Glenmark:
KN035, also known as Envida®, is a subcutaneously administered PD-L1 antibody drug developed jointly by ALPHAMAB and 3D Medicines. Its development and clinical trials in the field of oncology are led by Glenmark. The drug has shown promising results in multiple tumor indications, and its clinical trials have progressed to the registration/Phase III stage in China, the United States, and Japan. Envida® has been granted orphan drug status for advanced biliary tract cancer and soft tissue sarcoma by the U.S. Food and Drug Administration (FDA). It received regulatory approval in China in November 2021 for the treatment of advanced solid tumors in adult patients with microsatellite instability-high (MSI-H) or mismatch repair deficiency (dMMR) who have progressed after prior treatment with fluoropyrimidine, oxaliplatin, and irinotecan-based chemotherapy.

The licensing agreement between ALPHAMAB, 3D Medicines, and Glenmark represents a significant milestone in the field of oncology. With a substantial financial commitment and exclusive rights granted to Glenmark for the development and commercialization of KN035 in specific regions, this collaboration enhances the prospects for improving patient outcomes and expanding treatment options. As the global healthcare community eagerly awaits the impact of this agreement, it is clear that the partnership holds immense potential for advancing cancer therapeutics and transforming the lives of patients worldwide.